Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of total neoadjuvant treatment versus standard perioperative FLOT for oesophageal adenocarcinoma
ISRCTN51679511Phase 2Recruiting
- Sponsor
- University of Dundee
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of docetaxel, oxaliplatin, fluorouracil, folinic acid, carboplatin and 2 more in esophageal adenocarcinoma (EAC) and gastroesophageal adenocarcinoma (3 arms), sponsored by University of Dundee. Primary endpoint: Treatment completion feasibility. Started Jun 2026; status: recruiting.
02
Drugs
docetaxeloxaliplatinfluorouracilfolinic acidcarboplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN51679511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51679511.